Werewolf Therapeutics

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

–  Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity –

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Werewolf Therapeutics is developing a "conditionally activated" interleukin-2 (IL-2) drug for the treatment of stage IV melanoma and metastatic cancers. The drug aims to deliver therapeutic doses of IL-2 selectively near the tumor, minimizing toxicity. Early data from phase 1 trials showed remarkable tolerability and PK/PD, as well as the faintest signals of efficacy.

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Werewolf Therapeutics (NASDAQ: HOWL ) stock is on the rise Friday after the company released preliminary data from the phase 1/1b clinical trial. This clinical trial is ongoing and has the company treating patients with advanced or metastatic solid tumors with its interleukin 2 INDUKINE molecule.

Why Is Werewolf Therapeutics (HOWL) Stock Up 20% Today?

WATERTOWN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) --  Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company's lead clinical program, WTX-124x2101. This clinical program is an ongoing, multi-center Phase 1/1b clinical trial of WTX-124, Werewolf's interleukin 2 (IL-2) INDUKINE molecule, in patients with advanced or metastatic solid tumors. The preliminary data will be presented today at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting in San Diego, California.

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California. Additional posters with preclinical data supporting the PREDATOR platform and INDUKINE product candidates will also be presented at the meeting.

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

WATERTOWN, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will participate in the following upcoming investor conferences in the month of September:

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Preliminary safety and biomarker results from the phase 1/1b study, using WTX-124 for the treatment of patients with solid tumors, expected Q4 of 2023. Another INDUKINE molecule being developed in the pipeline would be WTX-330, which is being advanced in a phase 1 open-label study treating patients with metastatic solid tumors and non-Hodgkin lymphoma. Werewolf has a collaboration agreement with Jazz Pharmaceuticals for the development of JZP898, an interferon alpha INDUKINE molecule, with potential milestone payments of up to $1.26 billion.

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago.

Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Tops Revenue Estimates

- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7t h-9th, 2023, in New York, NY.

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.56 per share a year ago.

Werewolf Therapeutics, Inc. (HOWL) Reports Q1 Loss, Tops Revenue Estimates

- Progressing Phase 1/1b clinical trial for IL-2 INDUKINE WTX-124 in advanced or metastatic solid tumors; initial first-in-human clinical data from monotherapy dose-escalation arm expected in 4Q 2023 -

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

WATERTOWN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that management will participate at the following conferences in the month of May:

Werewolf Therapeutics to Participate in May Investor Conferences

HOWL is in the clinic with both WTX-124 and WTX-330 and is set to report initial data from the phase 1 trial of WTX-124 in Q4'23. HOWL's partner JAZZ should file an Investigational New Drug Application for WTX-613 in 2023 and then enter the clinic, which could trigger a milestone to HOWL.

Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023

WATERTOWN, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research Online First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule. The article, entitled “mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity,” includes preclinical data that demonstrates that mWTX-330 delivers IL-12 selectively to the tumor microenvironment, where it stimulates a potent anti-tumor immune response [DOI: 10.1158/2326-6066.CIR-22-0705].

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 33.90% and 131.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Tops Revenue Estimates

– Initial first-in-human clinical data for IL-2 INDUKINE WTX-124 monotherapy expected in 4Q 2023 from Phase 1/1b clinical trial in advanced or metastatic solid tumors –

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

WATERTOWN, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023

CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.

Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023

WTX-330 is designed as systemically delivered, conditionally activated IL-12 therapy

Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330

WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th-16th, 2023.

Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference

Clear Channel Outdoor Holdings

Myomo

Tenaya Therapeutic

Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Werewolf Therapeutics Stock (HOWL)